StockNews.com Begins Coverage on Bio-Path (NASDAQ:BPTH)

Equities researchers at StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH) in a note issued to investors on Monday. The brokerage set a “sell” rating on the stock.

Bio-Path Stock Up 6.0 %

NASDAQ BPTH opened at $0.18 on Monday. The stock’s 50-day moving average price is $0.64 and its 200-day moving average price is $0.84. Bio-Path has a 52 week low of $0.12 and a 52 week high of $7.67.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.